Posted by Gary Schwitzer in Disease mongering, Drug industry, FDA
The Wall Street Journal Health Blog published an interesting inside look of – as they put it – “how drug makers can try to lay the groundwork for sales well before a new therapy hits the market.”
The topic is premature ejaculation.
Some might call the methods “disease-mongering.”
Comments are closed.
This story focuses on a family that may have a rare genetic mutation that increases their risk of heart disease. Unfortunately, the “rare” part wasn’t mentioned until 1,600 words into this 2,100 word story.
While this story adequately addressed 7 of our 10 criteria, the 3 on which it missed were significant omissions, yet could have been easily addressed.
Solid medical conference reporting, with many expert interviews and good context provided. Goes far beyond the conference presentation itself.
We will not display your name or e-mail address on the site, nor will we share youre-mail address with any third parties.
For site updates and news from Gary, find us on Twitter:
HealthNewsReview: @HealthNewsRevu
Gary Schwitzer: @garyschwitzer
Copyright © 2013 Health News Review
